The Lancet Oncology published a clinical update in Oncology on 10 Mar 2026.
The item focuses on Benmelstobart plus anlotinib versus pembrolizumab as first-line treatment for PD-L1-positive, advanced non-small-cell lung cancer (CAMPASS): a blinded, randomised, controlled, phase 3 trial.
Review the original article for the full source wording and details.